logo.png

  • HOME

  • ABOUT US

    • SOCIAL IMPACT

  • STRATEGY

    • GENE THERAPY
    • CELL THERAPY
    • RNA-BASED THERAPY
    • TARGETED THERAPIES
    • MICROBIOME

  • TEAM

  • PORTFOLIO

    • VENTURE PORTFOLIO
    • PAST PORTFOLIO

  • 4BATLE ICAV

  • NEWSROOM

  • CONTACT

  • More

    Use tab to navigate through the menu items.

    NEWSROOM

    • Dec 13, 2021

    4BIO Capital to Use Insig AI’s Technology to Accelerate the Discovery of Innovative Investments

    4BIO Capital to Use Insig AI’s Technology to Accelerate the Discovery of Innovative Investments
    ARCHIVE
    • December 2022
    • November 2022
    • October 2022
    • September 2022
    • June 2022
    • April 2022
    • March 2022
    • February 2022
    • January 2022
    • December 2021
    • October 2021
    • April 2021
    • March 2021
    • January 2021
    • December 2020
    • November 2020
    • October 2020
    • July 2020
    • June 2020
    • May 2020
    SEARCH BY TAGS
    • portfolio
    • 4BIO Ventures II
    • investment
    • Orchard Therapeutics
    • appointment
    • SparingVision
    • approval
    • collaboration
    • acquisition
    • advisory board
    • CodeBio
    • Spark Therapeutics
    • Takeda
    • AAV
    • ADC Therapeutics
    • Carisma
    • IPO
    • publication
    • Ray Therapeutics
    • Redpin Therapeutics
    • review
    • TiGenix
    • 4BATLE
    • AI
    • Araris
    • awards
    • BLA
    • clinical trials
    • EGLS
    • ETF
    • exit
    • grant
    • Harbor Capital
    • IND
    • Insig AI
    • Intellia
    • Kyowa Kirin
    • Luca Science
    • merger
    • Moderna
    • pricing
    • results
    • venture
    FOLLOW US
    PRI-Sig-Web-V1.png
    4BIO Capital is a trading name of 4BIO Partners LLP which is authorised and regulated by the Financial Conduct Authority (Reference Number 842764)

    4BIO Partners LLP is an SEC Registered Investment Advisor number 801-121342
    LEGAL
    © 2015-2022 by 4BIO Partners LLP